within Pharmacolibrary.Drugs.N_NervousSystem.N02A_Opioids.N02AD51_PentazocineAndNaloxone;

model PentazocineAndNaloxone
  extends Pharmacolibrary.Drugs.ATC.N.N02AD51
  // parameters inherited from base class, duplicate, uncomment and change if necesarry
  /*
  
    weight         = 70,
    F              = 0.2,
    Cl             = 3.8888888888888884e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 0.006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 600  
  */
  ;

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>PentazocineAndNaloxone</td></tr><tr><td>ATC code:</td><td>N02AD51</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2000</td><td>ml/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pentazocine and naloxone is a fixed-dose combination analgesic, where pentazocine is an opioid agonist-antagonist used for moderate to severe pain, and naloxone is an opioid antagonist added to deter misuse by injection. Pentazocine is approved and used clinically, often in formulations that include naloxone to decrease abuse potential.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects from available single-agent pentazocine and naloxone data; no dedicated, direct population PK study for the fixed combination published.</p><h4>References</h4><ol><li><p>Thigpen, JC, et al., &amp; Harirforoosh, S (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. <i>European journal of drug metabolism and pharmacokinetics</i> 44(5) 591â€“609. DOI:<a href=\"https://doi.org/10.1007/s13318-019-00552-0\">10.1007/s13318-019-00552-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31006834/\">https://pubmed.ncbi.nlm.nih.gov/31006834</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end PentazocineAndNaloxone;
